| Literature DB >> 22829955 |
Saeid Golbidi1, Azam Mesdaghinia, Ismail Laher.
Abstract
The metabolic syndrome is a clustering of obesity, diabetes, hyperlipidemia, and hypertension that is occurring in increasing frequency across the global population. Although there is some controversy about its diagnostic criteria, oxidative stress, which is defined as imbalance between the production and inactivation of reactive oxygen species, has a major pathophysiological role in all the components of this disease. Oxidative stress and consequent inflammation induce insulin resistance, which likely links the various components of this disease. We briefly review the role of oxidative stress as a major component of the metabolic syndrome and then discuss the impact of exercise on these pathophysiological pathways. Included in this paper is the effect of exercise in reducing fat-induced inflammation, blood pressure, and improving muscular metabolism.Entities:
Mesh:
Year: 2012 PMID: 22829955 PMCID: PMC3399489 DOI: 10.1155/2012/349710
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Comparison of definitions of the metabolic syndrome.
| WHO | EGIR | NCEP | IDF |
|---|---|---|---|
| Presence of one of the following: | Insulin resistance AND two or more of the following: | Presence of three of the following (2001): | Central obesity(13) AND any two of the following: |
| (i) DM | (i) Central obesity(4) | (i) Central obesity(6) | (i) Raised TG(14) |
| (ii) IGT | (ii) Dyslipidemia(5) | (ii) Dislipidemia(7) | (ii) ↓ HDL(15) |
| (iii) IFG | (iii) BP ≥ 140/90 | (iii) BP ≥ 130/85 | (iii) ↑ BP(16) |
| (iv) Insulin resistance | (iv) FBG ≥ 6.1 mmol/L (110 mg/dL) | (iv) FPG ≥ 6.1 mmol/L (110 mg/dL) | (iv) ↑ FBG(17) |
| AND two of the following: | Update (2004): | ||
| (i) BP ≥ 140/90 | (i) Elevated waist circumferences(8) | ||
| (ii) Dyslipidemia(1) | (ii) Elevated TG(9) | ||
| (iii) Central obesity(2) | (iii) Reduced HDL(10) | ||
| (iv) Microalbuminuria(3) | (iv) Elevated BP(11) | ||
| (v) Elevated fasting glucose(12) |
BP: blood pressure, DM: diabetes mellitus, EGIR: European Group for the Study of Insulin Resistance, FBG: fasting blood glucose, HDL: high density lipoproteins, IDF: International Diabetes Federation, IFG: impaired fasting glucose, IGT: impaired glucose tolerance, NCEP: US National Cholesterol Education Program, TG: triglycerides, WHO: World Health Organization.
(1)TG ≥ 1.695 mmol/L and HDL ≤ 0.9 mmol/L (male), ≤1.0 mmol/L (female).
(2)Waist/hip ratio > 0.90 (male) >0.85 (female), or body mass index > 30 kg/m2.
(3)Urinary albumin excretion ratio ≥ 20 μg/min or albumin/creatinine ratio ≥ 30 mg/g.
(4)Waist circumference ≥ 94 cm (male), ≥80 cm (female).
(5)TG ≥ 2.0 mmol/L and/or HDL < 1.0 mmol/L or treated for dyslipidemia.
(6)Waist circumference ≥ 102 cm or 40 inches (male), ≥88 cm or 36 inches (female).
(7)TG ≥ 1.7 mmol/L (150 mg/dL) and HDL < 40 mg/dL (male), <50 mg/dL (female).
(8)Men, greater than 40 inches (102 cm) and women, greater than 35 inches (88 cm).
(9)Equal to or greater than 150 mg/dL (1.7 mmol/L).
(10)Men, Less than 40 mg/dL (1.03 mmol/L) and women, Less than 50 mg/dL (1.29 mmol/L).
(11)Equal to or greater than 130/85 mm Hg or use of medication for hypertension.
(12)Equal to or greater than 100 mg/dL (5.6 mmol/L) or use of medication for hyperglycemia.
(13)Defined as waist circumference with ethnicity specific values (If BMI is >30 kg/m², central obesity can be assumed and waist circumference does not need to be measured).
(14)TG > 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality.
(15)HDL < 40 mg/dL (1.03 mmol/L) in males, <50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality.
(16)systolic BP > 130 or diastolic BP > 85 mm Hg, or treatment of previously diagnosed hypertension.
(17)FPG > 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes.